Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2008

View Archived Issues

Bendamustine-rituximab combination active in relapsed mantle cell and indolent B-cell lymphoma

Phase II study assesses dose titration, depression with intranasal antiobesity drug PYY-3-36

Novartis: Q3 review

Activity seen with OSI-930 in phase I study in solid tumor patients

Further Empatic clinical data show improved quality of life, early responses

Nefopam acts against shivering in healthy volunteers

Recent Tufts College and TransTech patents disclose novel antidiabetic agents

Recent Xenon, Merck Frosst and GSK patents impart novel analgesic agents

Novexel reports positive phase II NXL-103 results in adults with CAP

Newron reports positive safety and tolerability results for HF-0220 in AD

DUSA reports results for phase IIb Levulan PDT trial in acne

Schering-Plough updates recent pipeline and business developments

NMS and Genentech sign collaboration agreement for antibody drug conjugates in cancer

New drug delivery agents reported in recent Emisphere Technologies patent

FDA maintains clinical holds on two IND applications for Dynavax and Merck & Co.'s Heplisav

ViroPharma completes acquisiton of Lev Pharmaceuticals

Vernalis regains rights to portfolio of antiinflammatory compounds including V-85546

Glycotex initiates enrollment in phase IIb study of GLYC-101 in wound healing

ALK reports positive results from first follow-up year in GT-08 clinical study of Grazax

Vitae reacquires full rights to renin inhibitor program for hypertension from GSK

CytoDyn files new IND for proof-of-principle study to reconfirm dose range of Cytolin

Addrenex initiates phase II ADX-415 trial in hypertension

Medivir submits MAA to European regulatory authorities for Lipsovir

Opexa provides additional data for Tovaxin in multiple sclerosis

EMEA recommends temporary suspension of Acomplia marketing authorization in obese patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...